Mishpacha Holdings Corp Makes New $487,000 Investment in United Therapeutics Corporation $UTHR

Mishpacha Holdings Corp bought a new position in United Therapeutics Corporation (NASDAQ:UTHR) in the fourth quarter, Holdings Channel.com reports. The firm bought 1,000 shares of the biotechnology company’s stock, valued at approximately $487,000. United Therapeutics comprises about 0.4% of Mishpacha Holdings Corp’s investment portfolio, making the stock its 11th biggest holding.

A number of other hedge funds also recently made changes to their positions in UTHR. Torren Management LLC bought a new stake in shares of United Therapeutics during the 4th quarter valued at approximately $26,000. Activest Wealth Management lifted its stake in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares during the last quarter. Entrust Financial LLC bought a new position in United Therapeutics in the 4th quarter valued at approximately $31,000. Wilmington Savings Fund Society FSB boosted its position in United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 49 shares in the last quarter. Finally, Harbor Capital Advisors Inc. acquired a new stake in United Therapeutics in the fourth quarter valued at approximately $48,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR opened at $536.59 on Friday. The firm has a 50 day moving average price of $564.47 and a two-hundred day moving average price of $523.41. The stock has a market cap of $22.78 billion, a P/E ratio of 19.81, a price-to-earnings-growth ratio of 1.75 and a beta of 0.57. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. During the same quarter last year, the firm posted $6.63 EPS. United Therapeutics’s revenue for the quarter was down 1.6% on a year-over-year basis. Analysts predict that United Therapeutics Corporation will post 26.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Oppenheimer upped their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Cantor Fitzgerald raised their price objective on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. UBS Group boosted their price objective on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Royal Bank Of Canada lowered their target price on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday, June 11th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $619.42.

Insider Transactions at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $558.40, for a total transaction of $5,584,000.00. Following the transaction, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at approximately $10,540,358.40. The trade was a 34.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 644,468 shares of company stock worth $364,004,497. 8.60% of the stock is owned by company insiders.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.